Pfizer Patent Infringement Lawsuit
Novo Nordisk, a Danish diabetes pharmaceutical company, filed suit against Pfizer on August 1, 2006, claiming patent infringement. The lawsuit seeks both compensatory damages and injunctive relief. Novo sought a preliminary injunction preventing the release of Pfizer's planned September 2006 launch of the diabetes drug. A federal judge, however, delayed any decision on Novo Nordisk's request for injunctive relief until at least December 4, 2006 when a court hearing is scheduled in the case. Pfizer's answer contends that Novo wants to deny diabetics access to Exubera, the only FDA approved inhaled insulin, and interfere with the company's pharmaceutical business.
On December 14, 2006 a federal judge denied Novo Nordisk's request for a preliminary injunction to halt sales of Pfizer's inhaled insulin. The patent lawsuit, however, has not been dismissed, and Pfizer's legal defenses are preserved. The pharmaceutical companies are still litigating in court over their respective inhaled insulin patent claims, a process that could take some time to resolve.
Read more about this topic: Inhalable Insulin
Famous quotes containing the words patent and/or infringement:
“This is the patent age of new inventions
For killing bodies, and for saving souls,
All propagated with the best intentions.”
—George Gordon Noel Byron (1788–1824)
“Necessity is the plea for every infringement of human freedom. It is the argument of tyrants; it is the creed of slaves.”
—William Pitt, The Younger (1759–1806)